CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
SYN-004 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02473640
NCT02473640Phase 2Completed

A Phase 1b/2a, Multi-Center, Open-Label, 2-Period, Fixed-Sequence Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Healthy Adult Subjects With a Functioning Ileostomy

Theriva Biologics, Inc.·interventional·Posted Jun 16, 2015·Updated Nov 27, 2018

In Brief

A Phase 2 clinical trial evaluating SYN-004, Esomeprazole, and 1 other intervention for Healthy Volunteers With Ileostomy. Completed, enrolled 15 participants across 2 sites.

Detailed Summary

A Phase 1b/2a, Multi-Center, Open-Label, 2-Period, Fixed-Sequence Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Healthy Adult Subjects with a Functioning Ileostomy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 16, 2015
Enrollment StartJun 1, 2015
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.0 years ago

Interventions

SYN-004drug

Esomeprazoledrug

Ceftriaxonedrug